EMA Withdrawn: Valtropin (somatropin) — BioPartners GmbH

View source ↗

Summary

Valtropin (somatropin) by BioPartners GmbH has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dwarfism Pituitary
• Turner Syndrome

Drugs mentioned

• Valtropin (somatropin)

Snippet

Status: Withdrawn. Therapeutic area: Turner Syndrome;Dwarfism, Pituitary. MAH: BioPartners GmbH. Decision date: 10/05/2012